diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine + hepatitis b vaccine (recombinant)

Pentacel + Engerix-B refers to the clinical co-administration of two distinct vaccine products to provide comprehensive immunization against six major pediatric diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, invasive disease caused by *Haemophilus influenzae* type b (Hib), and hepatitis B. **Pentacel** (Sanofi Pasteur) is a pentavalent vaccine consisting of diphtheria and tetanus toxoids, acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3), inactivated poliovirus (types 1, 2, and 3), and a Hib capsular polysaccharide (PRP) conjugated to tetanus toxoid. **Engerix-B** (GSK) is a monovalent recombinant hepatitis B vaccine containing hepatitis B surface antigen (HBsAg) produced in yeast cells. This combination is typically administered to infants as part of the primary vaccination series at 2, 4, and 6 months of age. While they are separate injections, they are often studied and administered together to simplify the immunization schedule.

Other names

DTaP-IPV/Hib + HepBPentacel and Engerix-B co-administration